Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGB1 | P09429 | 1/20 | 0.47 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.46 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.46 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6859574 | 0.86 | KLKB1 (0.62) | HMGB1CXCL12KLKB1CTSBMMP9 | |
| SCHEMBL7455122 | 0.85 | LCK (0.47) | HMGB1CXCL12KLKB1CTSBMMP9 | |
| SCHEMBL13652492 | 0.84 | ALDH1A1 (0.50) | HMGB1CXCL12KLKB1CTSBMMP9 | |
| SCHEMBL1627397 | 0.84 | NR1H4 (0.51) | HMGB1CXCL12PTGER4CA12CA1 | |
| SCHEMBL22277895 | 0.84 | KLKB1 (0.51) | HMGB1CXCL12KLKB1CTSBMMP9 | |
| SCHEMBL2895902 | 0.82 | SIRT3 (0.43) | PTGER4MEN1KMT2A | |
| SCHEMBL11445335 | 0.82 | HMGB1 (0.46) | HMGB1CXCL12PTGER4CA1CA2 | |
| SCHEMBL19748200 | 0.82 | HMGB1 (0.46) | HMGB1CXCL12KLKB1CTSBMMP9 | |
| SCHEMBL1179532 | 0.82 | CYP4F2 (0.49) | HMGB1CXCL12KLKB1CTSBMMP9 | |
| SCHEMBL15177931 | 0.82 | KDM4E (0.50) | HMGB1CXCL12CA2KLKB1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
| CN-114163162-B | Mineral powder hardening grinding aid and grinding-aid process thereof | 常州坚鹏建材有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-114163162-A | Mineral powder hardening grinding aid and grinding-aid process thereof | 常州坚鹏建材有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-106831389-B | Method for producing carboxylic acid compound | 中国科学技术大学 | 2020-03-31 | — | — | CN | disclosed |
| EP-3394027-B1 | METHOD FOR PREPARING PHENOLICS USING A CATALYST | TNO (NL) | 2020-02-19 | — | — | EP | disclosed |
| US-10364203-B2 | Method for preparing phenolics using a catalyst | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2019-07-30 | — | — | US | disclosed |
| US-20190002379-A1 | Method for Preparing Phenolics Using a Catalyst | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2019-01-03 | — | — | US | disclosed |
| EP-3394027-A1 | METHOD FOR PREPARING PHENOLICS USING A CATALYST | Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO (NL) | 2018-10-31 | — | — | EP | disclosed |
| US-5837710-A | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 1998-11-17 | — | — | US | disclosed |
| US-5834467-A | AIDS TREATMENT; VIRICIDES | AGOURON PHARMACEUTICALS, INC. | 1998-11-10 | — | — | US | disclosed |
| US-5827859-A | ADMINISTERED TO TREAT AIDS; VIRICIDES | AGOURON PHARMACEUTICALS, INC. | 1998-10-27 | — | — | US | disclosed |
| US-5827891-A | FOR TREATMENT OF AIDS, BLOCKING REPLICATION OF HIV VIRUS | AGOURON PHARMACEUTICALS, INC. | 1998-10-27 | — | — | US | disclosed |
| US-5827858-A | ADMINISTERED TO TREAT AIDS | AGOURON PHARMACEUTICALS, INC. | 1998-10-27 | — | — | US | disclosed |
| US-5824688-A | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 1998-10-20 | — | — | US | disclosed |
| EP-0722439-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-07-24 | — | — | EP | disclosed |
| US-5484926-A | VIRICIDES AND ENZYME INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-01-16 | — | — | US | disclosed |
| WO-1995009843-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
| EP-0194352-A2 | Salicylate assay, tracers, immunogens and antibodies | ABBOTT LABORATORIES (US) | 1986-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10364203-B2 | Method for preparing phenolics using a catalyst | TYR, FDPS, COMT | HMGB1 1674/4885CXCL12 1986/4885PTGER4 3802/4885 |
| US-20190002379-A1 | Method for Preparing Phenolics Using a Catalyst | TYR, FDPS, COMT | HMGB1 1674/4885CXCL12 1986/4885PTGER4 3802/4885 |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | HMGB1 3254/4885CXCL12 3191/4885PTGER4 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.